Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 630.58K | 190.31K | 23.95K | 63.68K | 114.97K | 186.15K |
Gross Profit | 298.48K | 181.29K | -146.37K | -209.88K | -24.78K | -281.53K |
EBITDA | 1.14K | -600.60K | -842.81K | 0.00 | -215.92K | -845.40K |
Net Income | -418.15K | -506.61K | -724.97K | -1.24M | -338.79K | -598.09K |
Balance Sheet | ||||||
Total Assets | 150.77K | 24.68K | 89.29K | 441.52K | 132.40K | 34.74K |
Cash, Cash Equivalents and Short-Term Investments | 52.34K | 4.58K | 65.05K | 415.73K | 99.21K | 9.16K |
Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 300.00K | 1.30M |
Total Liabilities | 486.73K | 553.85K | 505.88K | 365.68K | 678.88K | 2.40M |
Stockholders Equity | -335.96K | -529.17K | -416.60K | 75.84K | -546.47K | -2.36M |
Cash Flow | ||||||
Free Cash Flow | -290.02K | -60.46K | -350.69K | -195.78K | 90.04K | -22.09K |
Operating Cash Flow | -290.02K | -60.46K | -350.69K | -195.78K | 90.04K | -22.09K |
Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financing Cash Flow | 340.43K | 0.00 | 0.00 | 512.30K | 0.00 | 0.00 |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
68 Neutral | $1.61B | ― | -10.89% | ― | 17.79% | 11.08% | |
61 Neutral | AU$18.38M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
61 Neutral | AU$18.38M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
50 Neutral | AU$1.52B | 1.82 | -28.25% | 3.28% | 16.21% | -7.40% | |
46 Neutral | AU$7.32M | ― | -245.01% | ― | -17.50% | 66.33% | |
42 Neutral | $390.79M | ― | -133.28% | ― | 72.47% | 20.08% | |
42 Neutral | $390.79M | ― | -133.28% | ― | 72.47% | 20.08% | |
28 Underperform | AU$1.06M | ― | ― | 1110.63% | 30.61% |
333D Limited reported an increase in cash receipts from customers, totaling $268,339 for the quarter ending March 2025, marking a 1.92% rise from the previous quarter. The company secured two new contracts with healthcare providers, generating over $690,000 in revenue from July to March 2025, reflecting its growing presence in digital asset management and 3D printing services. The net operating cash received was $23,012, and the company incurred expenditures of approximately $245,643, with no material events occurring after the quarter.
333D Limited has appointed Mr. John Conidi as the new CEO and Managing Director, effective March 1, 2025. Mr. Conidi, a substantial shareholder and current director, has been pivotal in advancing the company’s digital asset management strategy, which has led to significant revenue growth in the medical digital asset sector. The company’s focus on R&D to automate processes aligns with the anticipated increase in radiology presentations due to government commitments to Medicare, potentially enhancing operational efficiency and cost-effectiveness for partners.